Insilico Medicine Publishes Positive Phase IIa Clinical Data for AI-Designed Rentosertib in Nature Medicine
July 29, 2026 • Source: Nature Medicine
Insilico Medicine published clinical validation for ISM001-055 (rentosertib), a first-in-class TNIK inhibitor with both target and molecular scaffold discovered by generative AI, in idiopathic pulmonary fibrosis (IPF).
**Executive Summary (2026-07-29):** Insilico Medicine published clinical validation for ISM001-055 (rentosertib), a first-in-class TNIK inhibitor with both target and molecular scaffold discovered by generative AI, in idiopathic pulmonary fibrosis (IPF). Source: Nature Medicine.
Technical Architecture & R&D Impact
In the randomized, double-blind, placebo-controlled Phase IIa trial across 71 IPF patients, rentosertib met its primary safety endpoint and demonstrated a dose-dependent Forced Vital Capacity (FVC) improvement of +98.4 mL at 12 weeks in the 60 mg QD cohort versus -62.3 mL in placebo. Total time from PandaOmics target discovery to IND-enabling studies took 18 months.
Enterprise Biopharma Procurement Takeaways
For computational biology leads, medicinal chemists, and R&D IT architects, this milestone underscores the rapid convergence of wet-lab experimental validation and scalable cloud foundation models during H2 2026. Teams evaluating vendors in the Clinical Readout category should benchmark API reproducibility, GxP audit readiness, and zero-data-retention VPC deployment terms.
Related Products
Published July 29, 2026
More NewsLast updated: July 29, 2026
